Why do people infected with the human immunodeficiency virus (HIV) often suffer from cardiovascular, liver, and other comorbidities? Researchers at the Centre for Individualised Infection Medicine (CiiM) investigated this question as part of the 2000HIV study, a multi-omics cohort coordinated by several research centers in the Netherlands. They identified various molecules and mechanisms that could be linked to the development of these comorbidities. The scientists are making the extensive results of their study freely available. They hope that they will be used for new research approaches and lead to a better understanding of the underlying causes and to helpful therapies. The researchers have now published their study results in the journal Nature Medicine. The CiiM is a joint institution of the Helmholtz Centre for Infection Research (HZI) and Hannover Medical School (MHH).

The former President of Hannover Medical School (MHH) and Clinical Director of the Helmholtz Centre for Infection Research (HZI), Prof. Michael P. Manns, passed away on 15 August 2025. Manns succumbed to a tumor disease at the age of 73. As a renowned gastroenterologist, he belonged to the worldwide scientific elite, was one of the most cited scientists, and enriched both the German and international research landscape as an excellent communicator. Until the very end, Manns was still actively involved in research at the MHH and promoted the scientific organization of the Centre for Individualised Infection Medicine (CiiM), a joint institution of the HZI and the MHH, which he co-founded. Manns also supported another joint center of the HZI and MHH, the TWINCORE, with his extensive expertise.

A balanced gut microbiome not only contributes to digestion, but is also an important protective factor against infections. Researchers at the Helmholtz Centre for Infection Research (HZI) led by Prof. Till Strowig, scientist in the German Center for Infection Research (DZIF), want to harness the power of the microbiome to prevent serious infections. They have discovered that bacteria of the species Klebsiella oxytoca can displace pathogenic bacteria from the gut and want to develop a living biotherapeutic based on this finding. The DZIF is now providing 2.2 million euros in funding for product development until the first tests on humans.